Notes from the Peply team

Retatrutide in 2026: Current Research and Where It Stands

Retatrutide is Eli Lilly's Phase 3 investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Here is what the TRIUMPH data shows, how it compares to semaglutide and tirzepatide, and what regulatory status means in 2026.